RNAC
$7.18
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Intraday
Recent News
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?
Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why We're Watching Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownership
Key Insights Insiders appear to have a vested interest in Cartesian Therapeutics' growth, as seen by their sizeable...
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +9.52% and +4.18%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?
Cartesian Therapeutics, Inc. (RNAC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.